Rasagiline
- TRADE NAMES: Agilect; Azilect (Teva)
- INDICATIONS: Parkinsonism
- CLASS: Monoamine oxidase B inhibitor
- HALF-LIFE: 0.6–2.0 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminophylline, Amitriptyline, Ciprofloxacin, Citalopram, Dextromethorphan, Entacapone, Fluoxetine, Fluvoxamine, MAO inhibitors, Meperidine, Paroxetine Hydrochloride, Pethidine, Pseudoephedrine, SSRIs, Viloxazine
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see two reviews of rasagiline in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 12/22/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric